title: [Update in neurocysticercosis treatment].
abstract: BACKGROUND
  Neurocysticercosis is the most frequent central nervous system parasitosis, although quite infrequent in our country. Its rising incidence can be explained by immigration from regions of the world where this disease is endemic.
  
  
  OBJECTIVE
  This paper reviews treatment options for this condition. PATIENTS AND METHODS. Eight patients have been diagnosed with neurocysticercosis in the last three years in our hospital. Patient age, sex, origin, symptoms, CT and MR images, diagnostic tests, treatment and duration of medical treatment and clinical and neuroradiological evolution are examined.
  
  
  RESULTS
  Patient age ranged from 25 to 33 years, all eight came from South America and the most frequent initial symptom was an epileptic crisis. Two patients had a single lesion, six had multiple lesions and all eight showed the lesion in the parenchyma. Only 50% showed a positive serum ELISA test for Taenia solium. Initial treatment was surgical in only one patient and the other seven received albendazol. In one of the latter the drug was ineffective and surgery was undertaken. A ten month follow up period has found a favorable evolution in all the patients, who are all also asymptomatic at the present time.
  
  
  CONCLUSIONS
  Neurocysticercosis is more common among immigrants than the local population in Spain. The initial treatment should be medical, with surgery as an option for non responders. We believe that duration of the medical treatment will depend on the patient and the clinico radiological evolution of his/her disease.
authors.affiliation: Servicio de Neurocirugía, Hospital Universitario La Paz, Madrid, España. cperezhulp@yahoo.es
authors.forename: C
authors.initials: C
authors.lastname: Pérez-López
authors.forename: A
authors.initials: A
authors.lastname: Isla-Guerrero
authors.forename: F
authors.initials: F
authors.lastname: Alvarez
authors.forename: M
authors.initials: M
authors.lastname: Budke
authors.forename: J C
authors.initials: JC
authors.lastname: Fernández-Miranda
authors.forename: J F
authors.initials: JF
authors.lastname: Paz
authors.forename: M
authors.initials: M
authors.lastname: Pérez-Alvarez
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D015766:Albendazole / Q000627:therapeutic use; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use; D000947:Antigens, Helminth / Q000134:cerebrospinal fluid / Q000276:immunology; D001921:Brain / Q000000981:diagnostic imaging / Q000469:parasitology / Q000473:pathology; D004446:Echinococcus / Q000276:immunology / Q000302:isolation & purification; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D020019:Neurocysticercosis / Q000175:diagnosis* / Q000188:drug therapy / Q000469:parasitology; D014057:Tomography, X-Ray Computed
chemical_list: D000871:Anthelmintics; D000947:Antigens, Helminth; D015766:Albendazole
vernacular_title: Actualizacion en el tratamiento de la neurocisticercosis.